BioPharmSignal logoBioPharmSignal

Biotech News

Apellis Announces Eight Oral Presentations at the 49th Macula Society Annual Meeting

Apellis Pharmaceuticals (APLS)Apellis PharmaceuticalsCompany update

Company will debut five-year results from GALE study showing meaningful impact of early and continuous treatment with SYFOVRE ® (pegcetacoplan injection) WALTHAM, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that eight abstracts were

Related news

KYMRKymera2026-09-01 11:00 EST

Kymera Therapeutics Announces Presentations on KT-621, a First-in-Class, Oral STAT6 Degrader, at the European Respiratory Society and European Academy of Dermatology & Venereology Congresses

SABSSAB Biotherapeutics2026-09-22 12:30 EST

SAB BIO to Present SAB-142 Data at the 62nd Annual Meeting of the European Association for the Study of Diabetes

BMYBMYBristol-Myers Squibb Company2026-08-29 15:00 EST

Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) at the European Society of Cardiology (ESC) Congress 2026

ARWRArrowhead Pharmaceuticals2026-08-24 11:30 EST

Arrowhead Pharmaceuticals to Present New Clinical Data at the European Society of Cardiology Congress

REGNRegeneron Pharmaceuticals2026-08-19 20:05 EST

Regeneron Announces Investor Conference Presentations

XFORX4 Pharmaceuticals2026-09-08 11:00 EST

X4 Pharmaceuticals Announces Positive Outcome from FDA Type C Meeting

SABSSAB Biotherapeutics2026-10-01 12:30 EST

SAB BIO to Present SAB-142 Data at the Inaugural Breakthrough T1D Clinical & Research Congress

ARWRArrowhead Pharmaceuticals2026-09-29 11:30 EST

Arrowhead Pharmaceuticals to Host a Webinar with Interim Clinical Data from a Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies

TARAProtara Therapeutics2026-09-08 20:05 EST

Protara Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference

ANABAnaptysBio, Inc.2026-09-01 20:15 EST

Anaptys Announces Participation at the H.C. Wainwright 28th Annual Global Investment Conference

View all latest news

Apellis Pharmaceuticals

Complement C3 Biology Apellis Pharmaceuticals develops medicines that inhibit complement protein C3, a central control point in the complement cascade. Its portfolio applies the same core biology to retinal, hematologic and renal diseases. SYFOVRE SYFOVRE is an intravitreal pegcetacoplan therapy and the first approved treatment for...

Recent company news

APLSApellis Pharmaceuticals2026-03-31 10:59 EST

Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology

APLSApellis Pharmaceuticals2026-03-02 12:00 EST

Apellis Announces Mikael Dolsten, M.D., Ph.D., to Join Board of Directors

APLSApellis Pharmaceuticals2026-02-24 12:05 EST

Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

APLSApellis Pharmaceuticals2026-02-23 12:00 EST

Apellis Pharmaceuticals to Present at the TD Cowen 46th Annual Health Care Conference

APLSApellis Pharmaceuticals2026-02-19 12:00 EST

Apellis Announces Eight Oral Presentations at the 49th Macula Society Annual Meeting

Stock data

Close
41.03 USD
Market cap
5.25B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States